Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12443041 | 0.89 | POLB (0.47) | PIK3CDKDM4EALDH1A1TDP1POLB | |
| SCHEMBL28098432 | 0.86 | L3MBTL1 (0.40) | KDM4EALDH1A1TDP1POLBSMN1; SMN2 | |
| SCHEMBL22861611 | 0.85 | ALDH1A1 (0.39) | PIK3CDKDM4EALDH1A1TDP1POLB | |
| SCHEMBL12465587 | 0.85 | SMN1; SMN2 (0.39) | KDM4EALDH1A1TDP1POLBSMN1; SMN2 | |
| SCHEMBL13312886 | 0.84 | PIK3CD (0.55) | PIK3CDKDM4EALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL6975583 | 0.83 | SMN1; SMN2 (0.42) | KDM4EALDH1A1TDP1SMN1; SMN2L3MBTL1 | |
| SCHEMBL4732168 | 0.82 | SMN1; SMN2 (0.63) | PIK3CDKDM4EALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL7392553 | 0.81 | ARG1 (0.46) | POLBSMN1; SMN2LMNAHSD17B10S1PR5 | |
| SCHEMBL11308867 | 0.81 | SMN1; SMN2 (0.39) | PIK3CDKDM4EALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL12726853 | 0.79 | KDM4E (0.52) | PIK3CDKDM4EALDH1A1TDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322689-A1 | IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | SunVax mRNA Therapeutics Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322689-A1 | IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | SunVax mRNA Therapeutics Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-10676467-B2 | Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2020-06-09 | — | — | US | disclosed |
| EP-3327013-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20190002450-A1 | COMPOSITIONS FOR BINDING SPHINGOSINE-1-PHOSPHATE RECEPTOR 1 (S1P1), IMAGING OF S1P1, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2019-01-03 | — | — | US | disclosed |
| EP-3327013-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | Celgene Corporation (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-3061758-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9801868-B2 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| EP-1781661-B1 | VASOPRESSIN V1A ANTAGONISTS | VANTIA LTD (GB) | 2017-06-07 | — | — | EP | disclosed |
| US-20160346264-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2016-12-01 | — | — | US | disclosed |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2009-06-04 | — | — | US | disclosed |
| WO-2009032326-A1 | NEW TETRACYCLINE DERIVATIVES AS ANTIINFECTIVE AGENTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2009-03-12 | — | — | WO | disclosed |
| US-20090029965-A1 | Vasopressin V1a Antagonists | FERRING B.V. (NL) | 2009-01-29 | — | — | US | disclosed |
| EP-1940835-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-07-09 | — | — | EP | disclosed |
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | US | disclosed |
| EP-1781661-A2 | VASOPRESSIN V1A ANTAGONISTS | Ferring B.V. (NL) | 2007-05-09 | — | — | EP | disclosed |
| WO-2007036733-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| WO-2006021213-A2 | VASOPRESSIN V1A ANTAGONISTS | FERRING B.V. (NL) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | PIK3CD 1907/4885KDM4E 2621/4885ALDH1A1 1358/4885 |
| US-20160346264-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | PIK3CD 1730/4885KDM4E 2637/4885ALDH1A1 403/4885 |
| US-20190002450-A1 | COMPOSITIONS FOR BINDING SPHINGOSINE-1-PHOSPHATE RECEPTOR 1 (S1P1), IMAGING OF S1P1, AND METHODS OF USE THEREOF | S1PR1, S1PR2, S1PR3 | PIK3CD 701/4885KDM4E 4383/4885ALDH1A1 4353/4885 |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | PIK3CD 1730/4885KDM4E 2637/4885ALDH1A1 403/4885 |
| US-10676467-B2 | Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof | S1PR1, S1PR2, S1PR3 | PIK3CD 701/4885KDM4E 4383/4885ALDH1A1 4353/4885 |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | PIK3CD 1907/4885KDM4E 2621/4885ALDH1A1 1358/4885 |
| US-20230322689-A1 | IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | PHOSPHO1, SGMS1, PLIN3 | PIK3CD 70/4885KDM4E 4341/4885ALDH1A1 3500/4885 |
| US-20090029965-A1 | Vasopressin V1a Antagonists | AVPR1A, AVPR2, AVPR1B | PIK3CD 2747/4885KDM4E 2842/4885ALDH1A1 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.